✦ LIBER ✦

Rituximab improves response in relapsed/refractory DLBCL

Book ID: 120856913
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2004
Weight: 134 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200414480-00037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved therapeutic outcomes of DLBCL a

Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients

✍ Lymphoma Study Division of the Korean Cancer Study Group; Y. H. Park; J. J. Lee; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 188 KB

Use of rituximab in three children with

Use of rituximab in three children with relapsed/refractory Burkitt lymphoma

✍ Sinan Akbayram; Murat Doğan; Cihangir Akgün; Fatih Erbey; Hüseyin Çaksen; Ahmet 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 90 KB

Central nervous system (CNS) relapse in

Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab

✍ W. M. Tai; J. Chung; P. L. Tang; Y. X. Koo; X. Hou; K. W. Tay; R. Quek; M. Tao; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 258 KB

Bortezomib: responses in relapsed refrac

Bortezomib: responses in relapsed refractory myeloma

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 138 KB

Fludarabine, Bortezomib, Myocet® and rit

Fludarabine, Bortezomib, Myocet® and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma

✍ Enrico Orciuolo; Gabriele Buda; Matteo Pelosini; Mario Petrini 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB

Efficacy and safety of clofarabine in re

Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients

✍ Chadi Nabhan; Nancy Davis; Jacob D. Bitran; Angel Galvez; Walter Fried; Kathy To 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB 👁 2 views